3 results
Approved WMORecruiting
Primary To confirm superiority on body weight reduction of CagriSema 2.4 mg/2.4 mg versus placebo as adjuncts to reduced-calorie diet andincreased physical activity in participants with overweight or obesity. Secondary To confirm superiority of…
Approved WMORecruiting
The primary objective is to compare efficacy of MWA to the efficacy of SBRT with regards to the primary endpoint (local tumour progression free survival at 1 year [1-year LTPFS]) in patients with unresectable CRLM (3 - 5 cm) that are unsuitable for…
Approved WMOCompleted
Primary:Compare the efficacy of single IV injection with otilimab 90 mg in adults with severe pulmonary COVID-19 related disease.Secondary:Other aspects of efficacy. Safety and tolerability.